Germline <i>SMARCA4</i> Deletion as a Driver of Uterine Cancer: An Atypical Presentation-Reference-Cited by-同舟云学术

Germline SMARCA4 Deletion as a Driver of Uterine Cancer: An Atypical Presentation

Published:2022-10 Issue:6 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Navitski Anastasia¹^ORCID,Al-Rawi Duaa H.²^ORCID,Makker Vicky²³^ORCID,Weigelt Britta⁴^ORCID,Zamarin Dmitriy²³^ORCID,Liu Ying²³⁵^ORCID,Arnold Angela G.⁵^ORCID,Chui M. Herman⁴^ORCID,Mandelker Diana L.⁴^ORCID,Walsh Michael⁵^ORCID,DeLair Deborah F.⁶,Cadoo Karen A.⁷^ORCID,O'Cearbhaill Roisin E.²³

Affiliation:

1. Department of Obstetrics and Gynecology, Augusta University, Augusta, GA

2. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

3. Department of Medicine, Weill Cornell Medical College, New York, NY

4. Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

5. Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

6. Department of Pathology, New York University, New York, NY

7. St James's Hospital, Trinity College Dublin, Trinity St James's Cancer Institute, Dublin, Ireland

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00349

Reference68 articles.

1. The SWI/SNF complex in cancer — biology, biomarkers and therapy

2. The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer

3. SWI/SNF nucleosome remodellers and cancer

4. SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy

5. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors;Clinical Cancer Research;2024-04-04

2. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283;Gynecologic Oncology;2023-09

3. Deletions of DNA in cancer and their possible uses for therapy;BioEssays;2023-05-11